Expired activity
Please go to the PowerPak homepage and select a course.

Oncology Pharmacy Consults:
Advances in Soft-Tissue Sarcoma

Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by educational grants from Lilly & Co Inc.


Soft-tissue sarcomas (STSs) are a heterogeneous collection of rare tumors. As such, they can arise within any site of the body, including the extremities, trunk, retroperitoneum, and head and neck. There are over 50 different histological subtypes, which can make accurate diagnosis challenging. STS accounts for about 58% of all sarcomas with the remainder diagnosed as sarcomas of the bone and viscera. Outcomes for patients with STS are poor, and local recurrence and metastases are common. The development of new treatments for patients with STS has been stymied by its rarity, which has a limited the number of clinical trials, trial participants, and new agents. However, recently, 4 new therapies have been approved for treating patients with high-grade STS. This activity will explore the challenges in the current care of patients with STS and prospects for improved, more personalized therapy approaches in the future.


The goal of this activity is to provide pharmacists with knowledge that can be applied to developing a treatment plan for their patients with STS.


This curriculum will meet the educational needs of oncology pharmacists who care for patients with STS. No prerequisites required.


The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • IDENTIFY clinical and pathological characteristics of STS and challenges of traditional treatment strategies.
  • EVALUATE the efficacy and safety of first-line STS treatments, including recent changes to clinical practice guidelines.
  • DESIGN a treatment plan for second-line STS therapy, incorporating newly approved agents utilized in various subtypes of STS.


acpeThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.0 contact hour of credit (0.10 CEU) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) reading and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-17-219-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Published: December 8, 2017
Expires: December 8, 2018

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 60 minutes


Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you thsat you did not pass the post-test. You will have 3 opportunities to pass the post-test.


As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:


David S. Ettinger, MD
Professor of Oncology, Otolaryngology – Head and Neck Surgery,
    and Radiation Oncology and Molecular Radiation Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Dr Ettinger reports serving as a principal investigator for Golden Biotechnology Corp; serving as a consultant for AbbVie, Inc, BeyondSpring Pharmaceuticals Inc, Boehringer-Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono Inc, Guardant Health Inc, Genentech Inc, Helsinn Therapeutics Inc, Herron Therapeutics, and sanofi-aventis, US LLC.


Nita Ahuja, MD
Vice Chair of Academic Affairs
Department of Surgery
Professor of Surgery, Oncology, and Urology
The Johns Hopkins University School of Medicine
Director of Sarcoma and Peritoneal Surface Malignancy Program
The Johns Hopkins Hospital
Baltimore, Maryland
Dr Ahuja reports serving as a contracted researcher for Astex Pharmaceuticals and Cepheid; serving as a consultant for Johnson & Johnson; and for licensed biomarkers for Cepheid.

Chung-Shien Lee, PharmD, BCPS, BCOP
Assistant Clinical Professor
Department of Clinical Pharmacy Practice
St. John's University
College of Pharmacy and Health Sciences
Queens, New York
Dr Lee reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Bradley N. Reames, MD, MS
Complex General Surgical Oncology Fellow
Department of Surgery
Johns Hopkins Hospital
Baltimore, Maryland
Dr Reames reports having no relevant financial or advisory relationships with corporate organizations related to this activity.


In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.


The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.


A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.


The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5



Oncology Pharmacy Consults:
Advances in Soft Tissue Sarcoma
Nita Ahuja, MD, Chung-Shien Lee, PharmD, BCPS, BCOP , and Bradley N. Reames, MD, MS

Postassessment and Evaluation